US 11926668
Anti-PD-1 antibodies for treatment of lung cancer
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 11926668 (Anti-PD-1 antibodies for treatment of lung cancer) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K2039/55, A61K31/337